German pharmaceutical distributor Krieger to install IBS Pharma

Send to friend

INFORMATION: Free information is available from IBS on the subject in this story. Click here to request a copy

IBS has signed an agreement with the German pharma distribution company Krieger & Co. The pharma distribution software solution covers software, hardware and services with a total order value of EUR 880 000.

German pharmaceutical distributor Krieger & Co., headquartered in Koblenz, has decided to install IBS specialized software for pharmaceutical distribution in their operations. Krieger has 190 employees and an annual turnover of EUR 170 m (2006). The company has a history of over 200 years servicing pharmacies in the German market. Krieger runs one of the most modern pharma distribution operations in Europe with robots and other forms of automation for picking, packaging and handling deliveries to over 140 locations daily.

The new pharmaceutical distribution solution covers all major processes such as distribution, warehousing, inventory, requests and returns, multi distribution centres, AMT, RF-handling, financials, business intelligence and integration.

"The agreement with Krieger is of strategic importance since it expands our installed base of pharmaceutical distributors in the important German-speaking market. Krieger is at the leading edge of pharmaceutical distribution in Europe and we look forward to continuing to develop best practices together, establishing processes that enable even faster deliveries, increasing customer service and meeting continuously highregulatory and customer demands," says Lukas Hostettler, MD IBS German-speaking Europe.


About IBS

IBS AB, (XSSE: IBS B) is a world-leading provider of supply chain management solutions for distribution, demand-driven manufacturing, financials and business intelligence with group revenue of EUR 255 m. IBS' primary focus is large and mid-sized distributors as well as sales and manufacturing companies in international groups.

Comments (0)

Add a Comment

This thread has been closed from taking new comments.